Metformin

Journal articles and book chapters

06-21-2018 | Pathophysiology | Review | Article

The gut microbiome as a target for the treatment of type 2 diabetes

Aydin Ö, Nieuwdorp M, Gerdes V. Curr Diab Rep 2018; 18: 55. doi: 10.1007/s11892-018-1020-6

06-21-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

06-15-2018 | Semaglutide | Article

Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

06-14-2018 | Pioglitazone | Article

Pioglitazone use and risk of bladder cancer: A systematic literature review and meta-analysis of observational studies

Mehtälä J et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0360-4

06-12-2018 | Empagliflozin | Article

Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

06-09-2018 | Cardiovascular disorders | Review | Article

Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

06-08-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

06-06-2018 | Lifestyle interventions | Article

A peer-support lifestyle intervention for preventing type 2 diabetes in India: A cluster-randomized controlled trial of the Kerala Diabetes Prevention Program

Thankappan KR et al. PLoS Med 2018; 15: e1002575. doi: 10.1371/journal.pmed.1002575

06-05-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

06-01-2018 | DPP-4 inhibitors | Article

Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

05-28-2018 | Sulfonylureas | Article

Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments

Powell WR, Christiansen CL, Miller DR. Diabetes Ther 2018. doi: 10.1007/s13300-018-0443-z

05-25-2018 | Oral combination medications | Article

Characterization of the open-label lead-in period of two randomized controlled phase 3 trials evaluating dapagliflozin, saxagliptin, and metformin in type 2 diabetes

Mathieu C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0445-x

05-22-2018 | Cardiovascular disorders | Article

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9

05-19-2018 | Risk factors | Review | Article

Prioritising risk factors for type 2 diabetes: Causal inference through genetic approaches

Wittemans LBL, Lotta LA, Langenberg C. Curr Diab Rep 2018; 18: 40. doi: 10.1007/s11892-018-1009-1

05-19-2018 | Liraglutide (T2DM) | Article

Retrospective analysis of an insulin-to-liraglutide switch in patients with type 2 diabetes mellitus

Introduction: Insulin and the GLP-1 receptor agonist liraglutide are both effective in reaching glycemic targets. The efficacy of an insulin-to-liraglutide switch in an obese population with concurrent use of sulfonylurea and metformin is unknown. We assessed the efficacy and determinants of success of an insulin-to-liraglutide switch in these patients.

05-18-2018 | Type 2 diabetes | Review | Article

Combination glucose-lowering therapy plans in T2DM: Case-based considerations

Blonde L, Dipp S, Cadena D. Adv Ther 2018. doi: 10.1007/s12325-018-0694-0

05-18-2018 | Gestational diabetes | Review | Article

Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes

Yeung RO et al. Rev Endocr Metab Disord 2018. doi: 10.1007/s11154-018-9446-3

05-14-2018 | Insulin glargine | Article

Characteristics of insulin-naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: A meta-analysis of individual participant data from 3 randomized clinical trials

Cummings MH et al. Clin Diabetes Endocrinol 2018; 4: 10. doi: 10.1186/s40842-018-0059-2

05-09-2018 | Liraglutide (T2DM) | Article

Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years

Li Q et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0432-2

Next Previous